Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 10, 1999, Pages 1165-1169

  Anthony Jones, E ^a   Ten Kate, Fibo J W ^a   Ter Borg, Frank ^a   Houben, Martin ^a   Reesink, Henk W ^a   Chamuleau, Robert A F M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Mycophenolate mofetil; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; URSODEOXYCHOLIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIARRHEA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; NAUSEA; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; THERAPY; TREATMENT OUTCOME;

ALKALINE PHOSPHATASE; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; MIDDLE AGED; MYCOPHENOLIC ACID; URSODEOXYCHOLIC ACID;

EID: 0042173683     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. 1 Mackay IR, Gershwin ER. The nature of autoimmune disease. Semin Liver Dis 1997; 17:3-11.
2. 2 Metcalf J, Motchison H, Palmer JM, Jones DE, Bassendine MF, James OFW. Natural history of primary biliary cirrhosis. Lancet 1996; 458:1399-1402.
3. 3 Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis: a prospective study. Gastroenterology 1990; 98:1567-1571.
4. 4 Kaplan MM. The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Semin Liver Dis 1997; 17:129-136.
5. 5 Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Semin Immunopathol 1993; 14:353-380.
6. 6 Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136:5-28.
7. 7 Silverman Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mychophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997; 37:445-449.
8. 8 Jones EA, Bergasa NV. Immunosuppressive treatment of chronic liver disease. Ann NY Acad Sci 1993; 696:319-327.
9. 9 European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345:1321-1325.
10. 10 Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11 (suppl 8):S117-S119.
11. 11 Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy and safety. J Am Acad Dermatol 1987; 17:962-971.
12. 12 Combes B. Ursodeoxycholic acid in primary biliary cirrhosis. Semin Liver Dis 1997; 17:125-128.
13. 13 Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 1991; 101:1332-1338.
14. 14 Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid. J Hepatol 1993; 18:9-14.
15. 15 Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Weisner RH, Gores GJ, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 1995; 22:1158-1162.
16. 16 Bergasa NV, Jones EA, Kleiner DE, Rabin L, Park Y, Wells MC, et al. Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis. Am J Gastroenterol 1996; 91:295-299.